Janus Kinase Inhibitor

MIAMI BEACH, Fla. — Janus kinase inhibitors have a unique mechanism of action, giving them the potential to push the boundaries of efficacy in the treatment of inflammatory skin diseases, according to a speaker at South Beach Symposium.

In this video, Sebastian E. Sattui, MD, MS, discusses exciting research on polymyalgia rheumatica.

Careers in allergy and asthma can take physicians into private, corporate or academic work as well as into professional organizations. Michael S. Blaiss, MD, a new member of Healio’s Allergy/Asthma Peer Perspective Board, has done it all.

In rheumatology, the next generation of new therapies always seems to be just out of reach, or perpetually “only a few years” away. However, several novel, and not-so-novel, approaches are giving hope that the future may finally soon arrive.

Incretin-based therapies, which were developed for the treatment of diabetes and obesity because of their ability to target defects that are not addressed by other medications, are continuing to evolve.

A Janus kinase inhibitor may preserve beta-cell function for children and young adults recently diagnosed with type 1 diabetes, according to findings published in The New England Journal of Medicine.

SAN DIEGO — Kathryn Dao, MD, discusses a study presented at ACR Convergence 2023 that compared the initiation of TNF inhibitors with non-TNF inhibitor biologics or JAK inhibitors among patients with rheumatoid arthritis-associated interstitial lung disease.

Treatment with Janus kinase inhibitors may be associated with elevated odds of acne, especially among those with dermatologic conditions, according to a study.